Exenatide for parkinson disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 3 registered trials.

Why this status

  1. 21 Jan 2020: Trial started, NCT04305002
  2. 12 Mar 2020: Trial registered, NCT04305002

The trials

NCT01174810: Exendin-4 as a Treatment for Parkinson's Disease - Pilot Study

State
State not given
Phase
Phase 2
People
40 planned
Started
Jul 2010
Primary completion
Mar 2013
Arms
Exenatide
Results
None posted
  1. 4 Aug 2010: Trial registered

NCT03456687: Effects of Exenatide on Motor Function and the Brain

State
Completed
Phase
Phase 1
People
5 taking part
Started
5 Jun 2018
Primary completion
16 Oct 2020
Arms
Exenatide
Results
None posted
  1. 7 Mar 2018: Trial registered
  2. 5 Jun 2018: Trial started
  3. 25 Aug 2021: Trial completed

NCT04305002: Exenatide Treatment in Parkinson's Disease

State
State not given
Phase
Phase 2
People
60 taking part
Started
21 Jan 2020
Primary completion
10 Oct 2023
Arms
Exenatide
Results
None posted
  1. 21 Jan 2020: Trial started
  2. 12 Mar 2020: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Also known as Bydureon, Bydureon bcise, Byetta, Exenatide once weekly (EQW ).

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.